Overview
Overactive bladder syndrome (OAB) is defined by urgent and frequent urges to urinate associated with frequent night-time urination and sometimes urinary incontinence. Sacral neuromodulation (SNM) is now one of the second-line treatments for OAB.
The mode of action of SNM is still poorly understood but a number of data from recent scientific literature suggest that SNM may act, among other things, by altering the balance of the autonomic nervous system (ANS) - located at the interface between the urinary tract and the brain structures regulating the functioning of the urinary tract.
The aim of this study would therefore be to develop a predictive tool for the effectiveness of SNM.
Eligibility
Inclusion Criteria:
- Male of female ≥ 18 years
- OAB syndrome
- Indication for a two-staged SNM
- Under general anaesthesia with Remifentanil and Propofol
- Patient who has given written consent to participate in the trial
- Patient willing to comply with all study procedures and duration
Exclusion Criteria:
- Tibial neuro-stimulation (last 3 months)
- Sacral neuromodulation (last 3 months)
- Botulinum toxin A intra-detrusor injection (last 9 months)
- Pregnancy in progress
- Administrative reasons
- Guardianship/curatorship
